Compare Inovio Pharmaceuticals Inc (INO) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Tapestry, Inc. trades at $141.01 (market cap $28.51B). The key difference: Tapestry, Inc. is far larger — about 319.4× Inovio Pharmaceuticals Inc's market cap, and Tapestry, Inc. pays a 1.13% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TPR | |
|---|---|---|
Market Cap | $89.27M | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $160.49 |
52-Week Low | $1.05 | $95.69 |
Enterprise Value | $60.28M | $31.37B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TPR trades at $140.45, down 0.71% on the day, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 76.18% gross margin and 55.74% ROE, though net income margin fell to 8.44% in 2025. Recent quarters have consistently beaten EPS estimates, and analyst consensus is strongly bullish with a $183.88 price target. Cash flow trends are volatile, with 2025 showing a net outflow of $5.02B due to financing activities.
Outlook remains positive driven by earnings beats and digital growth, but high valuation ratios (P/E 43.13) and debt levels pose risks. The stock offers 31% upside to consensus target, supported by institutional buy ratings and strong brand momentum in luxury retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
